BACKGROUND: To evaluate efficacy and @entity137 of radio-chemotherapy (RCT) and MR-guided pulsed-dose-rate (PDR) adaptive brachytherapy (IGABT) for locally advanced @entity5 (LACC). MATERIAL AND METHODS: Between 2007 and 2014 85 @entity1 with FIGO stage 1B1 N+ or >=  1B2 @entity5 were treated with RCT+ IGABT. The treatment consisted of a pelvic   paraaortic external beam radiotherapy (EBRT) (45-50.4 Gy    10 Gy boost to @entity5 and/or to pathologic lymph nodes) with concurrent @entity900 followed by 25-35 Gy of PDR IGABT in 30-50 pulses. The ratio of 3D-CFRT/IMRT was 61/24 @entity1 . Dose-volume parameters of high-risk clinical target volume (HR-CTV), intermediate-risk clinical target volume (IR-CTV) and D2cm(3) organs at risk (OARs) were reported. Local control (LC), @entity5 -specific survival (CCS) and @entity1349 ( @entity1349 ) were analyzed actuarially and morbidity crude rates were scored using CTCAEv4.0. RESULTS: Mean follow-up was 36 months (range 6-94). The mean D90 and D98 for HR-CTV was 84.4    9 Gy and 77    8.1 Gy, while for IR-CTV was 69.1    4.3 Gy and 64.8    4.3 Gy, respectively. The mean D2cm(3) for OARs was the following: bladder: 77.3    10.5 Gy, rectum: 65    6.8 Gy, sigmoid: 63    7.9 Gy and intestine: 64.0    9.1 Gy. Three year LC, CSS and @entity1349 were: 94%, 85% and 81%. The three-year regional- and distant control rates were 95% and 74%. Node negative @entity1 had significantly higher three-year CSS (100 vs. 72%, p = 0.016) and @entity1349 (92 vs. 72%, p = 0.001) compared to node positive ones. Three-year actuarial late Grade >=  3 morbidity was the following: GI: 8%, GU: 5%, Vaginal: 8%. The frequency of Grade >=  3 hematological @entity137 including @entity417 / @entity1431 / @entity1398 / @entity882 were 8.6%/34.7%/24.3%/24.3%, respectively. CONCLUSION: This large mono-institutional experience builds up further evidences that IGABT in conjunction with RCT should be the standard of care for @entity1 suffering LACC.

Clinical efficacy and @entity137 of radio-chemotherapy and magnetic resonance imaging-guided brachytherapy for locally advanced @entity5 XXXX : A mono-institutional experience.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity', 'toxicities'] @entity417 :: ('MESH:D000740', 'Disease') :: ['anemia'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity5 :: ('MESH:D009369', 'Disease') :: ['cancer', 'primary tumor', 'cervical cancer'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin'] @entity1398 :: ('MESH:D009503', 'Disease') :: ['neutropenia'] @entity1431 :: ('MESH:D007970', 'Disease') :: ['leukopenia'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'overall survival']
@entity1 :: (9606,Species) :: ['patients']
